Search PubMed⌕ Search

Biomedical subjects

N W Levin

Publications and source records attributed to N W Levin.

At least 73 records · Page 4Linked to original sources
PubMed1999

High clearance continuous renal replacement therapy with a modified dialysis machine.

Recent studies suggest that the dialysis dose significantly affects survival in acute renal failure (ARF) patients and that bicarbonate dialysate improves acid-base balance during continuous renal replacement therapy (CRRT). These data inspired us to use slow continuous dialysis (SCD) in the treatment of ARF. SCD is defined by the following parameters: (a) blood flow (Q(B)) = 100 to 200 ml/min, (b) dialysate flow (Q(D)) = 100 to 300 ml/min, (c) the use of a modified hemodialysis machine with controlled ultrafiltration and online production of bicarbonate-based dialysate, and (d) continuous or extended daily treatment for 8 to 24 hours. SCD provides a urea clearance in the 70 to 80 ml/min range. Preliminary data from an ongoing clinical trial demonstrate the safety, efficiency, and simplicity of the treatment.

Acute Kidney Injury↗
PubMed1998

Time on dialysis.

This article discusses the following three aspects of dialysis that are related primarily in that they deal with time (ie, the duration of dialysis treatments): (1) Which is better: long or short daily dialysis? (2) Does everyone need long dialysis? (3) How does time affect the measurement of the dialysis dose? As a working definition, short implies the least time necessary to provide equilibrated Kt/V or double-pool Kt/V (eKt/V) of 1.0 and remove intradialytic weight gain without symptoms. This article makes the following statements regarding time on dialysis: (1) The duration of the dialysis treatment for daily dialysis has different effects on the removal of small and large molecules. (2) Longer treatments are definitely indicated for some patients with poor compensation for rapid ultrafiltration. (3) Short treatments with high rates of clearance/volume are associated with more postdialysis urea rebond. It is therefore an advantage to express doses as equilibrated Kt/V.

Humans↗
PubMed1998

Initial results of a new access device for hemodialysis technical note.

BACKGROUND: A new subcutaneous device (DIALOCKtrade mark) provides vascular access to patients who currently require hemodialysis (HD). The device consists of a port-like valve, implanted subcutaneously below the clavicle, which provides a linear flow passage to two catheters placed in the right atrium via the internal or external jugular vein. The valve is accessed percutaneously with needle-cannulas that functionally convert the device to twin catheters for connecting the patient to the HD lines. METHODS: The device was implanted in 10 outpatients under local anesthesia. Patients used the device during dialysis 3 times/week, and data were collected on blood flow, pressures, adverse events and patient and nurse satisfaction. RESULTS: The device was used for HD almost immediately (median 3 days after implantation) and functioned successfully for more than nine months (mean +/- SD 7.3 +/- 1.5) in all but one patient who died of unrelated causes after one month; there were >800 dialysis sessions total. Blood flows over 300 ml/min were consistently achieved (average 326 +/- 40) with venous and arterial pressures of 200 +/- 44 and -246 +/- 29 mm Hg, respectively. After 66 patient-months, condition of the needle puncture sites remained satisfactory. Five systemic infections occurred in four patients, producing 2.3 bacteremic episodes per 1000 patient-days. All resolved without the need for device removal. There were no infections at the puncture sites. Two patients required fibrin sheath stripping of their catheters, one whose heparin lock was not changed for 23 days (for reasons unrelated to the device). Patient and nurse acceptance was excellent. CONCLUSION: The device represents a positive improvement in the area of HD access.

Adult↗
PubMed1998

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.

Elevated serum phosphorus is a predictable accompaniment of end-stage renal disease (ESRD) in the absence of dietary phosphate restriction or supplemental phosphate binders. The consequences of hyperphosphatemia include the development and progression of secondary hyperparathyroidism and a predisposition to metastatic calcification when the product of serum calcium and phosphorus (Ca x PO4) is elevated. Both of these conditions may contribute to the substantial morbidity and mortality seen in patients with ESRD. We have analyzed the distribution of serum phosphorus in two large national, random, cross-sectional samples of hemodialysis patients who have been receiving dialysis for at least 1 year. Data were obtained from two special studies of the United States Renal Data System, the Case Mix Adequacy Study (1990) and the Dialysis Morbidity and Mortality Study Wave 1 (1993). The relative risk of death by serum phosphorus quintiles is described after adjusting for age at onset of ESRD, race, sex, smoking status, and the presence of diabetes, the acquired immunodeficiency syndrome, and/or neoplasm. Logistic regression analysis is then used to describe the demographic, comorbid, and laboratory parameters associated with high serum phosphorus. Serum phosphorus was similar in these two study populations and averaged 6.2 mg/dL. Ten percent of patients had levels greater than 9 mg/dL and at least 30% of each group had serum phosphorus levels greater than 7 mg/dL. The adjusted relative risk of death by serum phosphorus level was not uniform across all quintiles, being constant below a level of 6.5 mg/dL and increasing significantly above this level. The relative risk of death for those with a serum phosphorus greater than 6.5 mg/dL was 1.27 relative to those with a serum phosphorus of 2.4 to 6.5 mg/dL. This increased risk was not diminished by statistical adjustment for coexisting medical conditions, delivered dose of dialysis, nutritional parameters, or markers of noncompliance. Evaluation of predictors of serum phosphorus greater than 6.5 mg/dL revealed in multivariate analysis that younger age at onset of ESRD, female sex, white race, diabetes, active smoking, and higher serum creatinine levels were all significant predictors. Analysis of serum calcium revealed no correlation with relative risk of death. The Ca x PO4 product, however, showed a mortality risk trend similar to that seen with serum phosphorus alone. Those in the highest quintile of the Ca x PO4 product (>72 mg2/dL2) had a relative mortality risk of 1.34 relative to those with products of 42 to 52 mg2/dL2. The relative mortality risk by log parathyroid hormone (PTH) level was elevated for patients with higher levels, but the mortality risk associated with hyperphosphatemia was independent of PTH. For hemodialysis patients who have been receiving dialysis for at least 1 year, we conclude that a large percentage have a serum phosphorus level above 6.5 mg/dL and that this places them at increased risk of death. This increased risk is independent of PTH. The mechanism(s) responsible for death is unknown, but may be related to an abnormally high Ca x PO4 product. Although mechanisms are not clearly established, this study supports the need for vigorous control of hyperphosphatemia to improve patient survival.

Adult↗
PubMed1998

Stability of access resistance during haemodialysis.

BACKGROUND: Access blood flow (Qac) is considered a useful indicator in the surveillance of haemodialysis access function. However, changes in Qac may be due to changes in blood pressure and/or to changes in access resistance (AR). METHODS: Weekly readings of Qac, cardiac output, and arterial blood pressure measured early and late during haemodialysis were obtained in 11 patients for a period of 3 weeks. Qac was determined from thermodilution of extracorporeal blood returning to the patient with reversed placement of blood lines and by measurement of arterial and venous blood temperatures in the extracorporeal circulation. Data are given as mean +/- SE. RESULTS: Qac dropped as mean arterial pressure (MAP) and total peripheral resistance (TPR) decreased, but increased when MAP and TPR increased. Linear regressions between the change in access flow and the change in MAP (deltaQac%=0.80*deltaMAP%-1.6, r2=0.39), and the change in TPR (deltaQac%= 0.54*deltaTPR%-9.2, r2=0.35) respectively, were significant (P<0.001). Whereas Qac significantly decreased (-8.4+/-3.3%, P<0.01) during the same treatment, AR remained unchanged (4.7+/-3.2%; P=NS). AR for all studies was 16.5+/-1.0 peripheral resistance units (1 PRU=2.226 kPa min l(-1)). There was a trend for resistance to increase (5.1+/-2.6%, P=NS) and for flow to decrease (-6.1+/-2.3%, P=NS) during the 3 weeks of the study. CONCLUSION: Qac measured during haemodialysis is variable and depends on haemodynamics, but AR is constant. AR is related to the physical structure of the peripheral access. Because of its intradialytic stability AR may be better suited as an indicator of access function.

Blood Pressure↗
PubMed1998

Dynamics of segmental extracellular volumes during changes in body position by bioimpedance analysis.

Extracellular volume (ECV) of arms, trunk, and legs determined from segmental bioimpedance data in 11 healthy men (31.6 +/- 7 yr) obtained at the end of a 30-min equilibration phase in the supine body position was compared with ECV determined from whole body measurements (ECVWB). ECV was calculated from extracellular resistance (RECV) identified from the bioimpedance spectrum for a range of 10 frequencies. Whole body RECV (527.6 +/- 55.6 Omega) was equal to the sum of RECV in the arms, trunk, and legs (241.6 +/- 36. 3, 49.2 +/- 5.1, and 236.3 +/- 25.5 Omega, respectively). The sum of equilibrated ECV in arms (1.31 +/- 0.25 liters), trunk (10.08 +/- 1.65 liters), and legs (2.80 +/- 0.82 liters) was smaller than ECVWB (20.90 +/- 2.59 liters). In six subjects who changed from a standing to a supine body position, ECV decreased in arms (-2.59 +/- 2.51%, P = NS) and legs (-10.96 +/- 3.02%, P < 0.05) but increased in the trunk (+4.2 +/- 3.2%, P < 0.05). ECVWB also decreased (-4.98 +/- 1. 41%, P < 0.05). However, the sum of segmental extracellular volumes remained unchanged (-0.06 +/- 0.07%, P = NS). The sum of segmental ECVs is not sensitive to changes in body position, which otherwise interferes with the estimation of ECV in bioimpedance analysis when ECVWB is used.

Adult↗
PubMed1998

Effects of controlled blood cooling on hemodynamic stability and urea kinetics during high-efficiency hemodialysis.

Although the use of cooled dialysate during hemodialysis is associated with stabilization of intradialytic BP, the effects of blood cooling on hemodynamics and urea kinetics in high-efficiency hemodialysis have not been completely studied. In particular, the effects of blood cooling have not been elucidated in very short-time, high K/V dialysis treatments, in which postdialysis urea rebound is maximized. In theory, blood cooling could increase urea compartmentalization during treatment and decrease dialysis efficacy. Measurements of cardiovascular hemodynamics and urea kinetics were performed in 15 patients (56 studies) during dialysis, using a blood temperature monitor with control of dialysate temperature. Dialysate temperature was adjusted to either lower the core temperature or raise the core temperature by, respectively, producing negative heat-energy exchange (cooled dialysis) or keeping heat-energy exchange in the extracorporeal circuit neutral (thermoneutral dialysis) so that energy was not transferred to or from the patient. Each subject was studied on both protocols, thereby allowing each individual to act as his own control. In cooled dialysis, heat-energy exchange in the extracorporeal circuit was -266+/-15 kJ per treatment, and dialysate temperature averaged 35.7+/-0.02 degrees C. In thermoneutral dialysis, heat-energy exchange in the extracorporeal circuit averaged 5+/-31 kJ per treatment, and dialysate temperature averaged 37.1+/-0.02 degrees C. Dialysate cooling resulted in a reduction in mean body temperature compared with thermoneutral therapy (-0.22+/-0.04 versus +0.31+/-0.05 degrees C). Cooling resulted in a greater increase in peripheral vascular resistance index (+515+/-160 versus + 114+/-92 dyn.sec/cm5 per m2), an increase in mean arterial pressure (+4+/-3 versus -4+/-4 mmHg), a reduction in the maximum intradialytic fall in mean arterial pressure (-10+/-2 versus -18+/-3, mmHg), and a reduction in staff interventions for hypotension or dialytic symptoms (6 of 28 versus 12 of 28 studies). These differences occurred without differences in the change in blood volume (-14.3+/-1.8% versus -13.9+/-2.2%) or cardiac index (-0.4+/-0.1 versus -0.4+/-0.2, L/min per m2). Urea rebound (37+/-4% versus 38+/-3%) and effective Kt/V (1.29+/-0.05 versus 1.32+/-0.06) were not different between groups. Thus, body temperature cooling can be used to stabilize BP and reduce intradialytic events requiring staff intervention without compromising the efficacy of treatment in high-efficiency dialysis.

Blood↗
PubMed1997

Clinical outcome relative to the dose of dialysis is not what you think: the fallacy of the mean.

Several recent retrospective studies of mortality relative to the dose of dialysis have been widely interpreted to indicate that adequate thrice-weekly hemodialysis requires a single pool Kt/V (spKt/V) of at least 1.4 to 1.6 and higher. In these studies, mortality rate has been correlated to the mean delivered spKt/V, (spKt/Vd)m, with coefficient of variation (CV) on the means ranging up to 45%. To evaluate these reported relationships, two large databases were analyzed using population constants to transform urea reduction ratio and spKt/Vd to equilibrated Kt/Vd (eKt/Vd), which expresses dose corrected for treatment time. The eKt/V dose (D) values were correlated to the reported relative risks (RR) of mortality to derive a RR/D function. The RR/D function, derived from these data with stepwise linear regression analysis, is nonlinear, with a steep linear increase in RR for eKt/Vd less than 1.05 and constant RR for eKt/Vd > or = 1.05. This RR/D function is mathematically expressed as RR = 1.96 - 1.03(eKt/Vd) (equation 1) when 0.50 < or = eKt/Vd < or = 1.05, and RR = 0.88 (equation 2) when eKt/V > or = 1.05. We show that regression of RR on (eKt/Vd)m with large CV results in overestimation of RR relative to eKt/Vd for individual patients because of extrapolation of the linear relationship beyond the threshold where the slope becomes zero (see equation 2 above). It is concluded that (1) current clinical data indicate that adequate dialysis is provided with eKt/Vd of 1.0 to 1.1 on a thrice-weekly schedule, (2) it is essential to assure that all patients achieve this level of therapy, which is best accomplished using urea kinetic modeling for both prescription and measurement of delivered eKt/Vd, and (3) the current HEMO study is well designed to determine whether higher levels of eKt/Vd will further improve clinical outcome.

Female↗
PubMed1997

Comparison of methods to predict equilibrated Kt/V in the HEMO Pilot Study.

The ongoing HEMO Study, a National Institutes of Health (NIH) sponsored multicenter trial to test the effects of dialysis dosage and membrane flux on morbidity and mortality, was preceded by a Pilot Study (called the MMHD Pilot Study) designed to test the reliability of methods for quantifying hemodialysis. Dialysis dose was defined by the fractional urea clearance per dialysis determined by the predialysis BUN and the equilibrated postdialysis BUN after urea rebound is completed (eKt/V). In the Pilot Study the blood side standard for eKt/V was calculated from the predialysis, postdialysis, and 30-minute postdialysis BUN. Four techniques of approximating eKt/V that eliminated the requirement for the 30-minute postdialysis sample were also evaluated. The first adjusted the single compartment Kt/V using a linear equation with slope based on the relative rate of solute removal (K/V) to predict eKt/V (rate method). The second and third techniques used equations or mathematical curve fitting algorithms to fit data that included one or more samples drawn during dialysis (intradialysis methods). The fourth technique (dialysate-side) predicted eKt/V from an analysis of the time-dependent profile of dialysate urea nitrogen concentrations (BioStat method; Baxter Healthcare, Inc., Round Lake, IL, USA). The Pilot Study demonstrated the feasibility of conventional and high dose targets of about 1.0 and 1.4 for eKt/V. Based on the blood side standard method, the mean +/- SD eKt/V for patients randomized to these targets was 1.14 +/- 0.11 and 1.52 +/- 0.15 (N = 19 and 16 patients, respectively). Single-pool Kt/Vs were about 0.2 Kt/V units higher. Results were similar when eKt/V was based on dialysate side measurements: 1.10 +/- 0.11 and 1.50 +/- 0.11. The approximations of eKt/V by the three blood side methods that eliminated the delayed 30-minute post-dialysis sample correlated well with eKt/V from the standard blood side method: r = 0.78 and 0.76 for the single-sample (Smye) and multiple-sample intradialysis methods (N = 295 and 229 sessions, respectively) and 0.85 for the rate method (N = 295). The median absolute difference between eKt/V computed using the standard blood side method and eKt/V from the four other methods ranged from 0.064 to 0.097, with the smallest difference (and hence best accuracy) for the rate method. The results suggest that, in a dialysis patient population selected for ability to achieve an equilibrated Kt/V of about 1.45 in less than a 4.5 hour period, use of the pre and postdialysis samples and a kinetically derived rate equation gives reasonably good prediction of equilibrated Kt/V. Addition of one or more intradialytic samples does not appear to increase accuracy of predicting the equilibrated Kt/V in the majority of patients. A method based on dialysate urea analysis and curve-fitting yields results for equilibrated Kt/V that are similar to those obtained using exclusively blood-based techniques of kinetic modeling.

Blood Urea Nitrogen↗
PubMed1997

The National Kidney Foundation Dialysis Outcomes Quality Initiative.

Rigorously developed clinical practice guidelines have the potential to change practice patterns to obtain improved patient outcomes. Toward that end, in March 1995 the National Kidney Foundation initiated the Dialysis Outcomes Quality Initiative, a comprehensive effort to create literature-based clinical practice guidelines in nephrology. Independent interdisciplinary work groups reviewed the available body of scientific literature on the following topics: hemodialysis adequacy, peritoneal dialysis adequacy, vascular access, and anemia. More than 11,000 papers were identified; of these approximately 1500 were found to be relevant, requiring formal structured review. Work groups formulated draft guidelines with supporting rationales that included the evidentiary basis for the recommendations. The draft guidelines were subjected to an unprecedented three-stage review process that involved more than 50 organizations from the renal community, including end-stage renal disease networks, patients dialysis providers, managed care organizations, and government. The finalized guidelines were issued in September 1997. Planned guideline implementation activities will focus on achieving the following: cooperation from the renal community; education of patients, clinicians, policy makers, and dialysis providers; information system tools to facilitate adoption of the guidelines; and evaluation strategies to determine whether practice patterns and outcome goals are achieved.

Humans↗
PubMed1996

High flux dialysis membranes improve plasma lipoprotein profiles in patients with end-stage renal disease.

A major cause of the morbidity and mortality of patients with end-stage renal disease (ESRD) is related to disorders of large blood vessels, especially coronary heart disease. Atherosclerosis, the most common form of this disease, is known to result from abnormalities in plasma lipoproteins, as well as from factors that damage the vessel wall. Two well-known risk factors for coronary heart disease are elevated plasma concentrations of LDL and reduced concentrations of HDL. This latter disorder is often accompanied by elevated triglycerides. Low HDL and elevated triglycerides are commonly associated with ESRD. Dialysis with high flux membranes differs from conventional dialysis in a number of ways. These include better biocompatibility and increased flux of larger molecules. Although several previous studies had suggested that dialysis with high flux membranes improves plasma lipoprotein profiles, a definitive cross-over designed study to assess the roles of high flux versus biocompatibility in altering lipoprotein profiles had not been done. Preliminary data from such a study are presented. These data confirm the beneficial effects of high flux membranes to reduce plasma triglycerides and suggest that this effect is primarily due to the high flux, and not the biocompatible, feature of the membranes.

Humans↗
PubMed1995

Solute disequilibrium and multicompartment modeling.

Mathematical models that simulate the exchange of solute between multiple body compartments have been used to study the distribution, elimination, and transport of urea, water, electrolytes, and other substances in the dialysis patient. Within a compartment, such substances are assumed to be uniformly distributed while exchange between compartments or with the environment may occur in a number of different ways. Diffusion in response to concentration gradients between, for example, intracellular and extracellular spaces, and convection due to blood flow have been identified as the most important transport mechanisms. Any system with more than one compartment may develop nonuniform solute distribution or solute disequilibrium between compartments. The minimum number of compartments required to model a kinetic process such as urea removal during hemodialysis depends on the accuracy and temporal resolution required, with higher resolution calling for more compartments. A two-compartment model is adequate for most clinical purposes. The physiological meaning or anatomic counterparts of the mathematical compartments remain uncertain as both flow and diffusion transport mechanisms contribute to the disequilibrium. Processes such as access and cardiopulmonary recirculation may be represented as additional compartments with small distribution volumes and high mass transport rates. Failure to recognize the effect of multiple compartments will result in an inaccurate measurement of dialysis dose and an inadequate hemodialysis prescription with a predictably poor clinical outcome. Allowance for compartment effects is particularly important in patients receiving treatment with a high ratio of dialyzer clearance to total body water, now commonly encountered during short-time, high-efficiency dialysis.

Biological Transport↗
PubMed1995

Is intercompartmental urea clearance during hemodialysis a perfusion term? A comparison of two pool urea kinetic models.

Analyses of intradialytic and postdialytic urea profiles call for models that consider delayed urea transfer from different parts of the body to the blood. There are two different approaches to the problem. In the classical cell membrane model it is assumed that the two compartments refer to the serial (s) arrangement of extracellular and intracellular volumes, whereas in the regional blood flow model the two compartments are identified as parallel (p) organ systems with high or low perfusion. In the cell membrane model, delayed urea removal from peripheral body compartments is governed by intercompartmental clearance (Kc) which is a function of cell membrane permeability, whereas in the regional blood flow model delayed urea removal is related to low perfusion (QL) of the large muscle/skin/bone compartment. Both models were compared in a set of 16 high-efficiency hemodialysis treatments. Modeled volumes (Vm,s = 31.2 +/- 9.5 L; Vm,p = 30.0 +/- 8.3 L) and modeled dose of hemodialysis (Kt/Vm,s = Kt/Vm,p = 1.12 +/- 0.33) were the same for both models. However, volumes modeled by either technique were significantly lower than anthropometric volumes (V alpha = 35.0 +/- 6.4 L). These data suggest that at this point the two models are experimentally indistinguishable. Moreover, the main system parameters of both models, Kc (0.54 +/- 0.16 L/min) and QL (0.63 +/- 0.15 L/min) showed a strong linear dependence (QL = 0.921 Kc + 0.139, r2 = 0.884), whereas no relation could be found between Kc and Vm. Therefore, delayed transport that has up to now been characterized by membrane permeability may also be explained by peripheral perfusion.

Adult↗
PubMed1995

The use of heated citric acid for dialyzer reprocessing.

Dialyzer reprocessing with heated water (100 to 105 degrees C) for 20 h can be used safely in lieu of chemical methods for disinfection. All infective agents including spores are destroyed and depyrogenation may occur. However, these temperatures may result in structural damage to the dialyzer, limiting reuse. Dialyzer reprocessing by using 1.5% citric acid heated to 95 degrees C for 20 h is an alternative method that produces equivalent microbiologic effects. Citric acid is well known as a disinfecting agent used for dialysis equipment. Because there is little structural damage to dialyzer components at 95 degrees C, reuse statistics are improved (mean reuse increased to 12.8). Both small and large molecule clearances and the sieving coefficient for protein are insignificantly altered by the process. Whereas the procedure is relatively simple, quality-assurance indicators are essential. The method has appeal because it avoids the use of chemical germicides. However, at present it has only been tested thoroughly in polysulfone dialyzers with heat-resistant polycarbonate casings and polyurethane resin. The clinical experience is favorable.

Citric Acid↗
PubMed1994

Analysis of the association of dialyzer reuse practices and patient outcomes.

This historic prospective study assessed the relationship between dialyzer reuse practices and hemodialysis patient mortality through 1 year of follow-up. Medicare patient demographic and survival data were combined with dialyzer reuse data from the Centers for Disease Control and Prevention's annual survey of dialysis-related diseases. Data were analyzed for the US Medicare hemodialysis population of never transplanted patients prevalent on January 1, 1989, and January 1, 1990, who were treated in freestanding dialysis units that used primarily conventional (not high-flux) dialyzers. Time to mortality, or transplant, and other censoring on December 31st of each year was regressed with proportional hazards models on patient, dialysis unit, and reuse measures. Age-, race-, and diagnosis-standardized mortality ratios for dialysis units were also regressed with weighted least squares techniques against dialysis unit and reuse measures. The results showed that patients treated in dialysis units that disinfected dialyzers with a peracetic acid, hydrogen peroxide, acetic acid mixture, or glutaraldehyde experienced higher mortality than patients treated in units that used formalin or in units that did not reuse dialyzers. The relative risk of mortality, compared with patients treated in nonreuse dialysis units, was 1.17 (P = 0.010) for glutaraldehyde and 1.13 (P < 0.001) for the peracetic acid mixture. The relative risk for formalin compared with the reference group of nonreuse was 1.06 (P = 0.088). With adjustment for several patient and dialysis unit characteristics, dialyzer reuse with certain germicides was associated with a significantly elevated mortality risk. This elevated risk, the etiology of which is currently not known, may represent a large number of potentially avoidable deaths per year. Only a large, nationally based analysis of this type has sufficient sample size to detect mortality risks such as these.

Dialysis↗